HC Wainwright & Co. Maintains Buy on Prelude Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a 'Buy' rating on Prelude Therapeutics (NASDAQ:PRLD) but lowers the price target from $6 to $5.

November 07, 2023 | 6:20 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Prelude Therapeutics' price target has been lowered from $6 to $5 by HC Wainwright & Co., though the 'Buy' rating is maintained.
The lowering of the price target by HC Wainwright & Co. could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained 'Buy' rating indicates that the analyst still sees potential in the company, which could counterbalance the negative sentiment to some extent.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100